These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21976243)

  • 41. Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
    Nishihori T; Alsina M
    Cancer Control; 2011 Oct; 18(4):258-67. PubMed ID: 21976244
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stem cell transplantation for pediatric lymphoma: past, present and future.
    Bradley MB; Cairo MS
    Bone Marrow Transplant; 2008 Jan; 41(2):149-58. PubMed ID: 18084337
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-dose chemotherapy followed by autologous and allogeneic hematopoietic stem cell transplantation in patients with follicular non-Hodgkin’s lymphoma in the rituximab era.
    Escobar IG; Sánchez de Ibarguen BC; de Juan VC; Alonso CM; García MM; Ruíz AC; Pulla MP
    Tumori; 2015; 101(1):2-7. PubMed ID: 25702654
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma.
    Dreger P; Laport GG
    Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):100-7. PubMed ID: 18162229
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review.
    Oliansky DM; Gordon LI; King J; Laport G; Leonard JP; McLaughlin P; Soiffer RJ; van Besien KW; Werner M; Jones RB; McCarthy PL; Hahn T
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):443-68. PubMed ID: 20114084
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
    Atilla E; Atilla PA; Demirer T
    Int J Hematol; 2017 Mar; 105(3):257-264. PubMed ID: 27995456
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Hematopoietic stem cell transplantation for malignant lymphoma].
    Asaoku H
    Nihon Rinsho; 2000 Mar; 58(3):704-8. PubMed ID: 10741150
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
    Epperla N; Fenske TS; Lazarus HM; Hamadani M
    Bone Marrow Transplant; 2015 Nov; 50(11):1393-404. PubMed ID: 26281033
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma.
    Kuruvilla J
    Blood; 2016 Apr; 127(17):2093-100. PubMed ID: 26989206
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of high-dose chemotherapy and autologous stem cell transplant for treatment-naΪve patients with peripheral T-cell lymphoma: a systematic review of the literature.
    Jethwa KD; Bishton MJ; Fox CP
    Br J Haematol; 2017 Aug; 178(3):476-479. PubMed ID: 27146257
    [No Abstract]   [Full Text] [Related]  

  • 51. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation.
    Cwynarski K; van Biezen A; de Wreede L; Stilgenbauer S; Bunjes D; Metzner B; Koza V; Mohty M; Remes K; Russell N; Nagler A; Scholten M; de Witte T; Sureda A; Dreger P
    J Clin Oncol; 2012 Jun; 30(18):2211-7. PubMed ID: 22547610
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas.
    Schmitz N; Lenz G; Stelljes M
    Blood; 2018 Jul; 132(3):245-253. PubMed ID: 29699989
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma.
    Bethge WA; von Harsdorf S; Bornhauser M; Federmann B; Stelljes M; Trenschel R; Baurmann H; Dittmann H; Faul C; Vogel W; Kanz L; Bunjes D
    Bone Marrow Transplant; 2012 Nov; 47(11):1397-402. PubMed ID: 22504934
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stem cell transplantation in Hodgkin lymphoma.
    Murphy F; Sirohi B; Cunningham D
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):297-306. PubMed ID: 17338650
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Autologous stem cell transplants in lymphomas.
    Vandenberghe EA; Goldstone AH
    Ann Med; 1996 Apr; 28(2):137-43. PubMed ID: 8732642
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reappraising the timing of transplant for indolent non-Hodgkin lymphomas.
    Capria S; Barberi W; Perrone S; Ferretti A; Salaroli A; Annechini G; D'Elia GM; Foà R; Pulsoni A
    Expert Rev Hematol; 2016 Oct; 9(10):951-64. PubMed ID: 27539362
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.
    Urbano-Ispizua A; Pavletic SZ; Flowers ME; Klein JP; Zhang MJ; Carreras J; Montoto S; Perales MA; Aljurf MD; Akpek G; Bredeson CN; Costa LJ; Dandoy C; Freytes CO; Fung HC; Gale RP; Gibson J; Hamadani M; Hayashi RJ; Inamoto Y; Inwards DJ; Lazarus HM; Maloney DG; Martino R; Munker R; Nishihori T; Olsson RF; Rizzieri DA; Reshef R; Saad A; Savani BN; Schouten HC; Smith SM; Socié G; Wirk B; Yu LC; Saber W
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1746-53. PubMed ID: 25981509
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia.
    Khouri IF
    Hematology Am Soc Hematol Educ Program; 2006; ():390-7. PubMed ID: 17124088
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
    William BM; Loberiza FR; Whalen V; Bierman PJ; Bociek RG; Vose JM; Armitage JO
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):417-23. PubMed ID: 23773453
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?
    Chaudhary L; Kharfan-Dabaja MA; Hari P; Hamadani M
    Bone Marrow Transplant; 2013 Nov; 48(12):1489-96. PubMed ID: 23584438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.